Who We Are
WSJ Medical Group is a healthcare technology company focused exclusively on EtO sterilization systems and facilities. We combine proprietary system design, modular scalability, and process optimization to help healthcare providers and manufacturers overcome sterilization shortages.
Our work supports hospitals, medical device manufacturers, and healthcare systems facing capacity constraints, rising costs, and regulatory pressure.
Executive Summary
The global medical device industry is approaching a regulatory and operational breaking point. More than 50% of all medical devices worldwide rely on Ethylene Oxide (EtO) sterilization. No viable alternative sterilization technology is expected for at least the next decade. At the same time, EtO is a known human carcinogen, and escalating EPA enforcement, community pressure, and litigation risk are forcing sterilization facilities to either modernize immediately or shut down.
WSJ Medical Group has developed and patented a multi-stage, near-zero-emission EtO treatment system that transforms a mandatory compliance cost into a revenue-generating asset. Our technology achieves >99.99% EtO treatment efficiency, converts recovered EtO into reusable chemicals, and enables sterilization facilities to remain operational while meeting the strictest regulatory standards.
This document defines WSJ Medical Group’s unified go-to-market (GTM) strategy: who we sell to, what problem we solve, how we win, and how we scale.
Our Mission
To strengthen healthcare supply chains by expanding access to safe, efficient, and scalable EtO sterilization capacity.
Our Values
- Patient safety and system reliability
- Regulatory awareness and responsibility
- Engineering-driven problem solving
- Long-term healthcare impact
Market Problem
Regulatory Crisis
- EtO classified as a human carcinogen
- EPA and local authorities actively shutting down sterilization plants
- Community opposition and litigation risk increasing
- FDA confirms no near-term alternative sterilization method exists
Industry Impact
- Forced shutdowns threaten the global medical supply chain
- Hospitals, device manufacturers, and distributors face catastrophic shortages
- Existing scrubber and filtration systems are inadequate under new regulations
Industry reality: Facilities must drastically reduce emissions or cease operations.
WSJ Solution Overview
Multi-Stage Zero-Emission EtO Treatment System
Unlike single-stage scrubbers or carbon filters, WSJ’s system neutralizes EtO across all concentration levels using an integrated, patented process.
Treatment Stages
- High & Medium Concentration Recovery
- High-pressure compression and PSA recovery
- Recovers 50–60% of EtO for direct reuse
- Chemical Asset Conversion
- Proprietary sulfonic acid reaction
- Converts EtO into polymer surfactant
- Removes >99% of EtO
- Produces a sellable industrial cleaning agent
- Low Concentration Neutralization
- Hydration treatment reduces exhaust to <1 mg/m³
- World-first 10-strain microbial degradation system
- 92% degradation efficiency at trace levels
- Bio-Monitoring Validation
- Living ecosystem (plants, plankton, fish)
- Real-time biological confirmation of safety
Result: Near-zero emissions with regulatory, environmental, and biological proof.
Value Proposition
WHY WE WIN
For Facility Owners
- Avoid forced shutdowns
- Achieve regulatory compliance
- Extend facility lifespan
- Reduce long-term operating risk
For Communities & Regulators
- Drastic reduction of carcinogenic emissions
- Transparent, biologically validated safety
- Reduced litigation and public opposition
For Investors & Partners Investors & Partnersr Investors & Partners
- Converts compliance cost into revenue
- Circular economy model
- First-mover advantage in a mandated market
Key Positioning: > WSJ does not replace EtO — we make EtO safe, compliant, and economically sustainable.
Market Size & Revenue Opportunity
Global EtO sterilization & exhaust treatment market: ~$1.25B annually
U.S. initial addressable market: ~90 high-risk facilities
Revenue Targets
- Capture 50% market share by 2026
- Target revenue: ~$500M
Revenue Streamsvenue Streams
- System installation & deployment
- Ongoing service & maintenance contracts
- Sale of recovered EtO
- Sale of polymer surfactant byproduct